Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02527486

Seoul National University Airway Registry

This is a multicenter, prospective observational cohort study, in which patients with chronic airway diseases including chronic obstructive pulmonary disease(COPD), asthma, asthma-COPD overlap syndrome (ACOS) will be recruited.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) Asthma Asthma With Chronic Obstructive Pulmonary Disease Bronchial Diseases Bronchiectasis Chronic Disease Chronic Obstructive Airway Disease Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Inactive Tuberculosis of Lung Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

COPD

Inclusion criteria

  • Postbronchodilator FEV1/FVC < 0.7 AND chronic respiratory symptom

Exclusion criteria

-

Asthma

Inclusion criteria

  • Never smoker or <5PY of smoking history AND Recurrent episodes of asthma symptoms (wheezing, dyspnea, chest tightness, cough) AND (either Positive BDR OR positive metacholine/mannitol/exercise provocation test)

Exclusion criteria

-

ACOS

Inclusion criteria

  • COPD AND Asthma (regardless of smoking status)

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Death (time to death)

    Time frame: upto 20 years

    death from any cause, death from COPD-specific cause, death from CVD, malignancy

Secondary outcomes

  1. post-bronchodilator FEV1 change rates

    Time frame: upto 20 years (at least 3 years)

Other outcomes

  1. Time to 1st exacerbation (definition of exacerbation is described below)

    Time frame: upto 20 years

    Definition of exacerbation: Airway disease symptom aggravation requiring either (1) Use of antibiotics or steroid, or (2) visiting ER or hospitalization

  2. Annual rate of exacerbation (definition of exacerbation is described below)

    Time frame: upto 20 years

    Definition of exacerbation: Airway disease symptom aggravation requiring either (1) Use of antibiotics or steroid, or (2) visiting ER or hospitalization

Study contacts

Contact information is provided by the study sponsor or research team.

Chang-Hoon Lee, M.D.

CONTACT

[email protected]

82-2-2072-4743

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Airway Registry for Chronic Airway Diseases

Important dates

Study start
2011
Primary completion
2021
Study completion
2031
First posted
Aug 19, 2015
Registry last updated
Aug 19, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.